BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 16579002)

  • 21. Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria.
    Zhang H; Zhang X; Hu C; Lu W
    Kidney Blood Press Res; 2012; 35(6):483-8. PubMed ID: 22687869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria.
    Heerspink HL; Greene T; Lewis JB; Raz I; Rohde RD; Hunsicker LG; Schwartz SL; Aronoff S; Katz MA; Eisner GM; Mersey JH; Wiegmann TB;
    Nephrol Dial Transplant; 2008 Jun; 23(6):1946-54. PubMed ID: 18089623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease.
    Sato A; Hayashi K; Saruta T
    Am J Hypertens; 2005 Jan; 18(1):44-9. PubMed ID: 15691616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pioglitazone shift circadian rhythm of blood pressure from non-dipper to dipper type in type 2 diabetes mellitus.
    Anan F; Masaki T; Fukunaga N; Teshima Y; Iwao T; Kaneda K; Umeno Y; Okada K; Wakasugi K; Yonemochi H; Eshima N; Saikawa T; Yoshimatsu H
    Eur J Clin Invest; 2007 Sep; 37(9):709-14. PubMed ID: 17696960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
    Miyazaki Y; DeFronzo RA
    Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
    Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
    J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms.
    Okada T; Wada J; Hida K; Eguchi J; Hashimoto I; Baba M; Yasuhara A; Shikata K; Makino H
    Diabetes; 2006 Jun; 55(6):1666-77. PubMed ID: 16731829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nephelometry in the clinical assessment of glomerular proteinuria and tubular function in diabetic nephropathy.
    Solerte SB; Severgnini S; Locatelli M; Cerutti N; Rondanelli M; Netti MA; Ferrari E; Fioravanti M
    Clin Nephrol; 1997 Sep; 48(3):151-8. PubMed ID: 9342486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal function preservation in type 2 diabetes mellitus patients with early nephropathy: a comparative prospective cohort study between primary health care doctors and a nephrologist.
    Martínez-Ramírez HR; Jalomo-Martínez B; Cortés-Sanabria L; Rojas-Campos E; Barragán G; Alfaro G; Cueto-Manzano AM
    Am J Kidney Dis; 2006 Jan; 47(1):78-87. PubMed ID: 16377388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
    Russo LM; del Re E; Brown D; Lin HY
    Diabetes; 2007 Feb; 56(2):380-8. PubMed ID: 17259382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy.
    Khajehdehi P; Roozbeh J; Mostafavi H
    Scand J Urol Nephrol; 2002; 36(2):145-8. PubMed ID: 12028688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transforming growth factor-beta in human diabetic nephropathy: effects of ACE inhibition.
    Langham RG; Kelly DJ; Gow RM; Zhang Y; Cordonnier DJ; Pinel N; Zaoui P; Gilbert RE
    Diabetes Care; 2006 Dec; 29(12):2670-5. PubMed ID: 17130203
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.
    Song JH; Lee SW; Suh JH; Kim ES; Hong SB; Kim KA; Kim MJ
    Clin Nephrol; 2003 Nov; 60(5):318-26. PubMed ID: 14640237
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Cytokines in noninvasive diagnostics of diabetic nephropathy progression].
    Senatorski G; Paczek L; Kropiewnicka E; Bartłomiejczyk I
    Pol Merkur Lekarski; 2002 Nov; 13 Suppl 1():28-32. PubMed ID: 12621778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
    Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
    J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.